Company news

Beam Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application

July 31, 2022

Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant

June 26, 2022

Beam Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

June 2, 2022

Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results

May 8, 2022

Beam Therapeutics to Present New Preclinical Data from Base Editing Pipeline at ASGCT 25th Annual Meeting

May 1, 2022

Beam Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference

March 24, 2022

Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare Conference

March 7, 2022

Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results

February 27, 2022

Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

February 8, 2022

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases

January 9, 2022

Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones

January 8, 2022

Beam Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 2, 2022

Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH

December 11, 2021

Beam Therapeutics Reports Preclinical Data Highlighting Multiplex Base Editing Approach to Create Anti-CD5 CAR T-cell Investigational Therapies for T-Cell Malignancies

November 11, 2021

Beam Therapeutics to Participate in the Jefferies 2021 Virtual London Healthcare Conference

November 10, 2021

Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results

November 7, 2021

Beam Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to its Board of Directors

November 7, 2021

Beam Therapeutics Announces Upcoming Preclinical Data Presentations at the American Society of Hematology Annual Meeting

November 3, 2021

Beam Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit

October 19, 2021

Beam Therapeutics Announces Preclinical Data Highlighting Base Editing Approach to Correct a Glycogen Storage Disease Type Ia Disease-Causing Mutation

October 18, 2021

Beam Therapeutics to Present Preclinical Data Highlighting Potential of CAR T Multiplex Base Editing Approach Targeting CD5 at 2021 SITC Annual Meeting

September 30, 2021

Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

September 27, 2021

Beam Therapeutics Announces Preclinical Data Highlighting Potential of Base Editors to Target Disease Drivers of Chronic Hepatitis B Infection

September 26, 2021

Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues

September 22, 2021

Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

September 7, 2021

Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results

August 9, 2021

Beam Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

August 2, 2021

Beam Therapeutics to Participate in the 2021 William Blair Biotech Focus Conference

July 7, 2021

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases

June 29, 2021

Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference

May 24, 2021

Beam Therapeutics Presents LNP Formulation Data at ASGCT and Reports First Quarter 2021 Financial Results

May 10, 2021

Beam Therapeutics Announces Oral and Poster Presentations at 24th American Society of Gene and Cell Therapy Annual Meeting

April 26, 2021

Beam Therapeutics Publishes Data Highlighting Ability to Rationally Design Base Editors for Precise Editing

April 19, 2021

Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer

March 14, 2021

Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results

March 14, 2021

Beam Therapeutics to Participate in the Barclays 2021 Global Healthcare Conference

March 3, 2021

Beam Therapeutics Announces Acquisition of Guide Therapeutics

February 22, 2021

Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors

January 18, 2021

Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh to its Board of Directors

January 10, 2021

Beam Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 4, 2021

Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease at ASH 2020

December 4, 2020

The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020

November 19, 2020

Beam Therapeutics Presents First Data Highlighting Base Editing Program for Glycogen Storage Disease Type Ia at AASLD

November 12, 2020

Beam Therapeutics Announces Business and Pipeline Progress and Reports Third Quarter 2020 Financial Results

November 9, 2020

Beam Therapeutics Names First CAR-T Base Editing Development Candidate for the Treatment of T-ALL and Presents New Data at SITC 2020

November 8, 2020

Beam Therapeutics to Participate in Chardan Virtual 4th Annual Genetic Medicines Conference

October 1, 2020

Beam Therapeutics Announces Pricing of Public Offering of Common Stock

September 29, 2020

Beam Therapeutics Announces Proposed Public Offering of Common Stock

September 27, 2020

Beam Therapeutics Announces First Development Candidates for Sickle Cell Disease and Reports Second Quarter 2020 Results

August 11, 2020

Beam Therapeutics to Participate in Upcoming Investor Conferences

July 29, 2020

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 14 decks. Every deck is listed under its year.